{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:08:57Z","timestamp":1789139337301,"version":"build-2803163510"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01598-5","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:34:55Z","timestamp":1786383295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth JC","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1690-1447","authenticated-orcid":false,"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malvika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darin","family":"Carabenciov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephens","family":"Haily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9434-5269","authenticated-orcid":false,"given":"Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"1598_CR1","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (\u2265 5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371.","journal-title":"J Clin Oncol"},{"key":"1598_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1598_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41408-025-01441-3","volume":"16","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Tan M, Parrondo R, Chhabra S, Dooley K, De Menezes Silva Corraes A, et al. Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late-onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J. 2025;16:18.","journal-title":"Blood Cancer J"},{"key":"1598_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, G\u00e1llego P\u00e9rez-Larraya J, van de Donk NW, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:32.","journal-title":"Blood Cancer J"},{"key":"1598_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01410-w","volume":"15","author":"P Rodr\u00edguez-Otero","year":"2025","unstructured":"Rodr\u00edguez-Otero P, Sidana S, Kouwenhoven M, Schecter JM, Lendvai N, De Braganca KC, et al. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4. Blood Cancer J. 2025;15:209.","journal-title":"Blood Cancer J"},{"key":"1598_CR6","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099\u2013103.","journal-title":"Nat Med"},{"key":"1598_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01384-9","volume":"15","author":"M Korenkov","year":"2025","unstructured":"Korenkov M, Liebaert J, Yousefian S, Schwartz S, Demel UM, Braune J, et al. Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy. Blood Cancer J. 2025;15:168.","journal-title":"Blood Cancer J"},{"key":"1598_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T cell\u2013associated neurotoxicity. Front Immunol. 2020;11:577027.","journal-title":"Front Immunol"},{"key":"1598_CR9","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/brain\/awz053","volume":"142","author":"DB Rubin","year":"2019","unstructured":"Rubin DB, Danish HH, Ali AB, Li K, LaRose S, Monk AD, et al. Neurological toxicities associated with chimeric antigen receptor T-cell therapy. Brain. 2019;142:1334\u201348.","journal-title":"Brain"},{"key":"1598_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0371-5","volume":"6","author":"AJ Giles","year":"2018","unstructured":"Giles AJ, Hutchinson M-KN, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6:51.","journal-title":"J Immunother Cancer"},{"key":"1598_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/cdd.2009.125","volume":"17","author":"M Woodward","year":"2010","unstructured":"Woodward M, De Boer J, Heidorn S, Hubank M, Kioussis D, Williams O, et al. Tnfaip8 is an essential gene for the regulation of glucocorticoid-mediated apoptosis of thymocytes. Cell Death Differ. 2010;17:316\u201323.","journal-title":"Cell Death Differ"},{"key":"1598_CR12","doi-asserted-by":"publisher","first-page":"e1009504","DOI":"10.1371\/journal.pcbi.1009504","volume":"18","author":"AB Brummer","year":"2022","unstructured":"Brummer AB, Yang X, Ma E, Gutova M, Brown CE, Rockne RC. Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy. PLOS Comput Biol. 2022;18:e1009504.","journal-title":"PLOS Comput Biol"},{"key":"1598_CR13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1598_CR14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/019459988509300202","volume":"93","author":"JW House","year":"1985","unstructured":"House JW, Brackmann DE. Facial nerve grading system. Otolaryngol\u2014Head Neck Surg. 1985;93:146\u20137.","journal-title":"Otolaryngol\u2014Head Neck Surg"},{"key":"1598_CR15","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations the Movement Disorder Society Task Force on rating scales for Parkinson\u2019s disease. Mov Disord. 2004;19:1020\u20138.","journal-title":"Mov Disord"},{"key":"1598_CR16","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1182\/bloodadvances.2025018853","volume":"10","author":"KJ Lim","year":"2026","unstructured":"Lim KJ, Lee HE, Chen ZE, Bledsoe A, Parrondo RD, Chhabra S, et al. Diagnosis and management of immune effector cell-associated enterocolitis (IEC-EC) following ciltacabtagene autoleucel. Blood Adv. 2026;10:4495\u2013507.","journal-title":"Blood Adv"},{"key":"1598_CR17","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1182\/bloodadvances.2025018639","volume":"10","author":"PA Forsberg","year":"2026","unstructured":"Forsberg PA, Turner JA, Meyer M, Abbott D, Nicholson S, Schade H. Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma. Blood Adv. 2026;10:3629\u201339.","journal-title":"Blood Adv"},{"key":"1598_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2010.04.005","volume":"335","author":"AE Coutinho","year":"2011","unstructured":"Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2\u201313.","journal-title":"Mol Cell Endocrinol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01598-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01598-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:14:30Z","timestamp":1789136070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01598-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1598"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01598-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.J.L., M.T., K.D., A.D., Ma.G., D.C., L.H., H.S., P.K., T.K., R.W., J.C., M.B., N.A., S.Z., U.Y., E.W., S.G.: no relevant disclosures; R.P.: advisory board role for Sanofi Aventis and Astra Zeneca, research funding from Bristol Myers Squibb Foundation and GlaxoSmithKline; S.C.: honoraria from Sanofi, Ascentage Pharma, Sobi, Legend Biotech, and research funding from Johnson & Johnson, Takeda, C4 Therapeutics, Abbvie, Ascentage Pharma, AstraZeneca; C.S.: consultancy for Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer; honoraria from Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda; other (travel expenses): Astra Zeneca, BeOne, Janssen-Cilag, Menarini Stemline, oncopeptides, Sanofi; Mo.G.: personal fees from Ionis\/Akcea, honorarium from Alnylym, personal fees from Prothena, personal fees from Sanofi, personal fees from Janssen, personal fees for Data Safety Monitoring board from Abbvie & Arcellex, fees from Johnson & Johnson, Honoraria for Astra Zeneca, Medscape, Dava Oncology. Alexion; P.K.: Honoraria: Pharmacyclics, Sanofi, BeiGene, MustangBio, AstraZeneca, AbbVie. Consulting or Advisory Role: Sanofi. Research Funding: Amgen, Takeda, Sanofi, AbbVie, GlaxoSmithKline, Sorrento Therapeutics, Karyopharm Therapeutics, Regeneron, Ichnos Sciences, Bristol Myers Squibb\/Celgene; P.L.B.: Consultant: Oncopeptidfes. Salarius, Radmetrix, Omeros, CellCentric, AbbVie, Pfizer; S.K.: Consulting or Advisory Role: Takeda, Janssen Oncology, Genentech\/Rocher, Abbvie, BMS\/Celgene, Pfizer, Regeneron, Sanofi, K36 Therapeutics; travel, accommodation and expenses: Abbvie, Pfizer; Research funding: Takeda, Abbvie, Novartis, Sanofi, Janssen Oncology, MedImmune, Roche\/Genentech, CARsgen Therapeutics, Allogene Therapeutics, GSK, Regeneron, BMS\/Celgene; S.A.: Consulting or Advisory Role: Takeda, BeiGene, GlaxoSmithKline, Sanofi, Pharmacyclics, BMS, Amgen, Janssen, Regeneron, Cellectar. Research Funding: Pharmacyclics, Janssen Biotech, Cellectar, BMS, Amgen, GlaxoSmithKline, AbbVie, Ascentage Pharma, Sanofi; R.F.: consultancy for AbbVie, Adaptive, Amgen, Apple, BMS\/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi. Scientific advisory board: Caris Life Sciences. Board of directors: Antengene. Patent for FISH in multiple myeloma. A.Z.: patents submitted for DACH1-IgG, PDE10A-IgG, CAMKV-IgG, Tenascin-R-IgG as biomarkers of neurological autoimmunity, received research funding from Roche\/Genetech and Center for MS and Autoimmune Neurology at Mayo Clinic not relevant to this study, Consulted without personal compensation for Alexion pharmaceuticals, steering committee for the KYSA-8 study for autologous CAR-T-19 treatment for SPS; no personal compensation; Y.L.: advisory board role for Janssen, Sanofi, BMS, Regeneron, Genentech, Tessera, Legend, NexT Therapeutics, steering committee for Janssen, Kite\/Gilead, research funding from Janssen, BMS, scientific advisory board for NexImmune, Caribou and data safety monitor board for Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study received approval from the Mayo Clinic Institutional Review Board (16-008261). All procedures adhered to applicable guidelines and regulations, and given the retrospective nature of this research, patient informed consent was not required.","order":2,"name":"Ethics","label":"Ethics approval, consent to participate and inclusion statement","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"153"}}